Table 1.
Summary of association results of the genome-wide association study
| |
|
|
|
ADR
b
|
Non-ADR
c
|
RAF |
P
value |
|
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHR | SNP | Gene | Allele 1/2 (risk) | 11 | 12 | 22 | 11 | 12 | 22 | ADR | Non-ADR | Allelic | Dominant | Recessive | OR a | 95% CI |
| 2 |
rs3820706 |
CACNB4 |
A/G (G) |
18 |
169 |
116 |
167 |
421 |
291 |
0.66 |
0.57 |
8.26E-05 |
1.07E-01 |
8.13E-09 |
3.71 |
(2.24-6.15) |
| 2 |
rs6725180 |
CACNB4 |
A/C (C) |
17 |
152 |
134 |
135 |
429 |
316 |
0.69 |
0.60 |
7.90E-05 |
1.11E-02 |
3.84E-06 |
3.05 |
(1.81-5.14) |
| 8 |
rs16908658 |
FAM135B |
G/A (G) |
30 |
93 |
180 |
23 |
286 |
571 |
0.25 |
0.19 |
1.07E-03 |
9.68E-02 |
9.93E-07 |
4.09 |
(2.34-7.17) |
| 10 |
rs7476422 |
PCDH15 |
T/G (G) |
4 |
47 |
252 |
34 |
245 |
601 |
0.91 |
0.82 |
1.20E-07 |
3.77E-07 |
3.58E-02 |
2.17 |
(1.60-2.93) |
| 10 |
rs857373 |
PCDH15 |
G/A (A) |
5 |
55 |
243 |
43 |
255 |
581 |
0.89 |
0.81 |
5.16E-07 |
3.15E-06 |
1.11E-02 |
2.00 |
(1.51-2.66) |
| 10 |
rs857392 |
PCDH15 |
G/A (A) |
5 |
55 |
243 |
42 |
252 |
584 |
0.89 |
0.81 |
9.08E-07 |
5.95E-06 |
1.60E-02 |
1.97 |
(1.48-2.62) |
| 10 |
rs1319836 |
PCDH15 |
C/T (T) |
5 |
55 |
243 |
42 |
254 |
583 |
0.89 |
0.81 |
9.10E-07 |
4.34E-06 |
1.60E-02 |
1.98 |
(1.49-2.63) |
| 10 |
rs7919725 |
PCDH15 |
A/G (G) |
5 |
56 |
242 |
42 |
256 |
580 |
0.89 |
0.81 |
9.94E-07 |
4.68E-06 |
1.60E-02 |
1.97 |
(1.48-2.60) |
| 10 |
rs857369 |
PCDH15 |
T/C (C) |
1 |
32 |
270 |
18 |
178 |
684 |
0.94 |
0.88 |
2.29E-06 |
7.25E-06 |
5.87E-02 |
2.33 |
(1.60-3.39) |
| 10 |
rs9416306 |
PCDH15 |
G/T (T) |
1 |
32 |
270 |
18 |
178 |
682 |
0.94 |
0.88 |
2.29E-06 |
7.13E-06 |
5.88E-02 |
2.34 |
(1.61-3.39) |
| 10 |
rs1219862 |
PCDH15 |
C/T (T) |
2 |
31 |
270 |
17 |
182 |
681 |
0.94 |
0.88 |
2.73E-06 |
5.08E-06 |
1.85E-01 |
2.28 |
(1.58-3.30) |
| 13 |
rs7318267 |
FARP1 |
C/T (T) |
11 |
149 |
143 |
108 |
387 |
385 |
0.72 |
0.66 |
6.69E-03 |
3.15E-01 |
4.09E-06 |
3.71 |
(1.97-7.01) |
| 13 |
rs2282048 |
FARP1 |
T/C (C) |
11 |
148 |
144 |
107 |
387 |
386 |
0.72 |
0.66 |
5.72E-03 |
2.84E-01 |
6.24E-06 |
3.68 |
(1.95-6.93) |
| 17 |
rs1530357 |
LOC100506974 |
A/G (A) |
57 |
170 |
76 |
114 |
417 |
349 |
0.47 |
0.37 |
1.11E-05 |
4.29E-06 |
1.39E-02 |
1.96 |
(1.45-2.63) |
| 17 |
rs1530361 |
LOC100506974 |
A/G (A) |
53 |
165 |
85 |
99 |
408 |
372 |
0.45 |
0.35 |
8.83E-06 |
1.12E-05 |
7.04E-03 |
1.54 |
(1.27-1.86) |
| 19 | rs11666971 | LASS4 | G/A (G) | 46 | 119 | 138 | 56 | 379 | 445 | 0.35 | 0.28 | 1.64E-03 | 1.43E-01 | 8.13E-06 | 2.63 | (1.74-3.96) |
aORs and CIs are calculated according to the associated genetic model; bindividuals who developed grade 2 alopecia; cindividuals who did not developed any ADRs after chemotherapy. CHR, chromosome; SNP, single nucleotide polymorphism; ADR, adverse drug reaction; RAF, risk allele frequency; OR, odds ratio; CI, confidence interval.